Postoperative pain - Pipeline Insight, 2021

Postoperative pain - Pipeline Insight, 2021

  • February 2021 •
  • 200 pages •
  • Report ID: 6022127 •
  • Format: PDF
“Postoperative pain - Pipeline Insight, 2021,” report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Postoperative pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Postoperative pain Understanding

Postoperative pain: Overview
Postoperative pain (CINV) are the side effects of cancer chemotherapy that can cause significant negative impacts on patients’ quality of life and on their ability to tolerate and comply with therapy. An estimated 80% of patients with cancer experience chemotherapy-induced nausea and vomiting. It includes emesis and nausea, which can involve a loss of appetite and result in decreased oral intake of fluids and calories. CINV can be classified into 5 types: acute, delayed, anticipatory, breakthrough, and refractory. The pathophysiology of CINV includes both peripheral and central nervous system (CNS) pathways with different mechanisms involved in acute CINV and delayed CINV. Risk factors for developing CINV can be classified as patient-related or treatment-related. Prevention is the primary goal in the management of CINV. The primary alternative for prevention and treatment include 5-HT3 receptor antagonists, NK1 receptor antagonists, and corticosteroids. Other medications used, but to a lesser extent, include dopamine antagonists, benzodiazepines, cannabinoids, and olanzapine.

"Postoperative pain - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Postoperative pain pipeline landscape is provided which includes the disease overview and Postoperative pain treatment guidelines. The assessment part of the report embraces, in depth Postoperative pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Postoperative pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Postoperative pain R&D. The therapies under development are focused on novel approaches to treat/improve Postoperative pain.

Postoperative pain Emerging Drugs Chapters
This segment of the Postoperative pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Postoperative pain Emerging Drugs

• HTX-011: Heron Therapeutics
HTX-011 (bupivacaine and meloxicam) is an investigational drug and is in development to reduce postoperative pain for 72 hours and reduce the need for opioid analgesics. It is an extended-release, dual-acting local anesthetic (DALA) applied into the surgical site. It utilizes a novel, synergistic mechanism of action that combines bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam. In September 2020, the European Commission (EC) granted a marketing authorization for ZYNRELEF (formerly known as HTX-011) for the treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults. In September 2020, based on USFDA meeting plans to resubmit the NDA for HTX-011 for the management of postoperative pain in the fourth quarter of 2020.

• CR845: Cara Therapeutics
CR845 is a peripherally acting kappa opioid receptor agonist. CR845 displayed no significant affinity for any other non-opioid known receptors. CR845 exhibits potent analgesic, anti-pruritic (anti-itch) and anti-inflammatory properties in both human and animals. CR845 is intrinsically poor at penetrating the blood-brain barrier, that’s why it has shown to produce little to no CNS-mediated side effects.
Further product details are provided in the report……..

Postoperative pain: Therapeutic Assessment
This segment of the report provides insights about the different Postoperative pain drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Postoperative pain
There are approx. 60+ key companies which are developing the therapies for Postoperative pain. The companies which have their Postoperative pain drug candidates in the most advanced stage, i.e. Registered include, Heron Therapeutics.

• Phases
report covers around 60+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Postoperative pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical

• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Postoperative pain: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Postoperative pain therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Postoperative pain drugs.

Postoperative pain Report Insights
• Postoperative pain Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Postoperative pain Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Postoperative pain drugs?
• How many Postoperative pain drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Postoperative pain?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Postoperative pain therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Postoperative pain and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Heron Therapeutics
• Cara Therapeutics
• Endo Pharmaceuticals
• Mylan
• Concentric Analgesics
• Camurus
• PainReform
• Layerbio
• Jiangsu HengRui Medicine
• Polypid
• Pharmaleads
• Layerbio
• Neumentum

Key Products
• HTX-011
• CR845
• Oxymorphone
• MR-107A-01
• Vocacapsaicin
• Buprenorphine depot
• HTX-034
• PRF 110
• Ketorolac ophthalmic implant
• Ropivacaine
• Ketorolac ophthalmic implant
• Research programme: controlled release pain therapeutics
• PL-37
• Ketorolac